X0202 SCHEDULE 13G 0001440771 XXXXXXXX LIVE Common Stock 06/17/2026 0001841330 Pasithea Therapeutics Corp. 70261F202 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 Rule 13d-1(c) Stonepine Capital Management, LLC b DE 0.00 1952550.00 0.00 1952550.00 1952550.00 N 5.8 IA OO The percentage reported herein is calculated based on 33,414,448 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ending March 31, 2026. Stonepine Capital, L.P. b DE 0.00 1952550.00 0.00 1952550.00 1952550.00 N 5.8 PN The percentage reported herein is calculated based on 33,414,448 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ending March 31, 2026. Stonepine GP, LLC b DE 0.00 1952550.00 0.00 1952550.00 1952550.00 N 5.8 OO The percentage reported herein is calculated based on 33,414,448 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ending March 31, 2026. Jon M. Plexico b X1 0.00 1952550.00 0.00 1952550.00 1952550.00 N 5.8 HC IN The percentage reported herein is calculated based on 33,414,448 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ending March 31, 2026. Pasithea Therapeutics Corp. 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139 Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, LP, a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of shares of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any shares of Common Stock covered by this Schedule 13G. 2900 NW Clearwater Drive, Suite 100-11, Bend OR 97703 See Item 4 of the cover sheet for each reporting person. Y Stonepine: 1,952,550 Partnership: 1,952,550 General Partner: 1,952,550 Jon M. Plexico: 1,952,550 Stonepine: 5.8% Partnership: 5.8% General Partner: 5.8% Jon M. Plexico: 5.8% Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 1,952,550 Partnership: 1,952,550 General Partner: 1,952,550 Jon M. Plexico: 1,952,550 Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0 Stonepine: 1,952,550 Partnership: 1,952,550 General Partner: 1,952,550 Jon M. Plexico: 1,952,550 Y N The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G Stonepine Capital Management, LLC /s/ Jon M. Plexico 06/23/2026 Stonepine Capital, L.P. /s/ Jon M. Plexico 06/23/2026 Stonepine GP, LLC /s/ Jon M. Plexico 06/23/2026 Jon M. Plexico /s/ Jon M. Plexico 06/23/2026